PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

Fox04-DRI: Research & Evidence

Early-Stage Research

Published research, clinical trial data, and evidence grading for Fox04-DRI across studied indications.

Back to Fox04-DRI overview

Research Summary

Fox04-DRI has zero human studies. All published in vivo evidence traces to a single 2017 Cell paper (Baar et al., PMID 29107983). The D-retro-inverso format creates uncharacterized bioavailability challenges. No pharmaceutical company has invested in development, and the senolytic field has moved toward other compounds.

Evidence by Indication (2 indications)

Indication Tier Trials Summary
Senolytic therapy Tier D 0 Disrupts FOXO4-p53 interaction to induce senescent cell apoptosis; mouse data only
Anti-aging Tier D 0 Restored fitness and fur density in aged mice; no human trials initiated

Graded using our evidence tier methodology.

Citations (6 sources)

  1. 1. FOXO4-D-Retro-Inverso targets extracellular matrix production in fibroblasts and ameliorates bleomycin-induced pulmonary fibrosis in mice. Study

    (2023), Naunyn-Schmiedeberg's archives of pharmacology

  2. 2. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway. Study

    (2022), Journal of cellular and molecular medicine

  3. 3. Targeting senescence-like fibroblasts radiosensitizes non-small cell lung cancer and reduces radiation-induced pulmonary fibrosis. Study

    (2021), JCI insight

  4. 4. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Study

    (2020), Aging

  5. 5. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Study

    Baar MP, Brandt RMC, Putavet DA, et al. (2017), Cell

  6. 6. Molecular regulative mechanisms of aging and interventional effects of Chinese herbal medicine. Study

    (2017), Zhongguo Zhong yao za zhi